Sanuwave to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Sanuwave Health (NASDAQ: SNWV) will attend the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12 to January 15, 2026. The company offers FDA-approved next-generation wound care products and said management will be available for meetings during the conference.

Investors or parties wishing to meet should contact investors@sanuwave.com to schedule a time.

Key Figures

Conference edition 44th Annual J.P. Morgan Healthcare Conference

Conference dates January 12–15, 2026 J.P. Morgan Healthcare Conference in San Francisco

Market Reality Check

$29.48 Last Close

Volume Pre-news volume of 161,354 shares is 1.82x the 20-day average of 88,535, indicating elevated trading interest ahead of this conference update. high

Technical Shares at $29.48 are trading below the 200-day MA of $33.06 and sit between the 52-week low of $18.50 and high of $46.59.

Peers on Argus

Peer performance is mixed with TCMD up 3% and DCTH up 2.8%, while CLPT, NPCE, and RXST are modestly negative. This pattern does not indicate a unified sector move around this conference-related news for SNWV.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 08	Commercial access update	Positive	-8.6%	UltraMIST added as option for Healogics iSupply members.
Nov 07	Earnings results	Positive	+17.7%	Record Q3 revenue, strong margins, and higher full-year outlook.
Nov 03	Earnings call notice	Neutral	+0.3%	Announcement of Q3 2025 earnings call logistics and replay details.
Nov 03	Reimbursement update	Neutral	-5.3%	CMS final 2026 fee schedule showing UltraMIST rates largely unchanged.
Oct 06	Prelim earnings update	Negative	+9.1%	Preliminary Q3 revenue below prior guidance and lowered 2025 outlook.

Pattern Detected

Recent news has sometimes shown divergence, with positive commercial updates occasionally met by negative price reactions, while core earnings reports have generally aligned with positive moves.

Recent Company History

Over the last few months, Sanuwave reported record Q3 2025 revenue around $11.5M with strong year-over-year growth and issued both preliminary and final results, generally drawing positive price reactions. A CMS reimbursement update for UltraMIST and the recent UltraMIST GPO addition produced mixed to negative short-term moves. Against that backdrop, this J.P. Morgan Healthcare Conference participation fits into an ongoing stream of commercial and investor-relations visibility events.

Market Pulse Summary

This announcement highlights Sanuwave’s participation in the 44th Annual J.P. Morgan Healthcare Conference from January 12–15, 2026, adding to recent visibility from record Q3 2025 results and reimbursement updates. Investors may watch for any new disclosures or strategic commentary delivered around the conference, especially in the context of prior guidance adjustments and recent commercial milestones such as the UltraMIST GPO addition.

Key Terms

fda-approved regulatory

"a leading provider of FDA-approved next-generation wound care products"

FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.

AI-generated analysis. Not financial advice.

EDEN PRAIRIE, Minn., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-approved next-generation wound care products, is pleased to announce that it will be attending the upcoming 44^th Annual J.P. Morgan Healthcare Conference in San Francisco, CA from January 12^th to January 15^th 2026.

Those wishing to meet with company management during the conference should reach out to investors@sanuwave.com to schedule a time.

About Sanuwave
Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive directed energy medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.

Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, and plans for future business development activities. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement, except as may be required by applicable law.

Contact: investors@sanuwave.com 

FAQ

When will Sanuwave (SNWV) attend the J.P. Morgan Healthcare Conference in 2026?

Sanuwave will attend the conference from January 12 to January 15, 2026.

Where is the 44th Annual J.P. Morgan Healthcare Conference that Sanuwave (SNWV) will attend?

The conference takes place in San Francisco, CA.

How can investors schedule a meeting with Sanuwave (SNWV) management at the conference?

Investors should email investors@sanuwave.com to request and schedule a meeting.

What does Sanuwave (SNWV) say about its products in the conference announcement?

The company describes itself as a provider of FDA-approved next-generation wound care products.

Will Sanuwave (SNWV) present results or financial guidance at the January 2026 conference?

The announcement only states Sanuwave will attend and offer meetings; it does not mention any scheduled presentations, results, or guidance.

Is Sanuwave (SNWV) accepting meeting requests for specific dates during the conference?

Yes; the company asks interested parties to contact investors@sanuwave.com to schedule meetings during January 12–15, 2026.